BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12673372)

  • 1. Evidence for the clinical use of infliximab in Crohn's disease.
    Turner SM; Probert CS
    Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract]   [Full Text] [Related]  

  • 3. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
    Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
    Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
    [No Abstract]   [Full Text] [Related]  

  • 4. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dutch guidelines for treatment with infliximab for Crohn's disease.
    Vermeire S
    Neth J Med; 2006; 64(7):210-1. PubMed ID: 16929081
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab and the bone in Crohn's disease.
    Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
    Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
    Lawrance IC
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
    [No Abstract]   [Full Text] [Related]  

  • 8. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
    van den Brande JM; Peppelenbosch MP; Hommes DW
    Gastroenterology; 2006 Oct; 131(4):1362-3. PubMed ID: 17030216
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn's disease.
    Schröder O; Naumann M; Stein J
    Aliment Pharmacol Ther; 2004 Oct; 20(7):823-4. PubMed ID: 15379845
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.
    Arnott ID; Shand A; Ghosh S
    Am J Gastroenterol; 2000 Nov; 95(11):3326-7. PubMed ID: 11095380
    [No Abstract]   [Full Text] [Related]  

  • 14. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
    Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
    Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
    [No Abstract]   [Full Text] [Related]  

  • 15. Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis.
    Persley K; Scherl E; Rubin P
    Am J Gastroenterol; 2001 Dec; 96(12):3444-5. PubMed ID: 11774971
    [No Abstract]   [Full Text] [Related]  

  • 16. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
    Papa A; Felice C; Marzo M; Guidi L
    Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
    Kume K; Yamasaki M; Yoshikawa I; Harada M
    Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
    [No Abstract]   [Full Text] [Related]  

  • 20. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.